Sarbu Luminita, Kitchell Barbara E, Bergman Philip J
1 Veterinary Oncology Center, Renton, WA, USA.
2 VCA Veterinary Care Referral Center, Albuquerque, NM, USA.
J Feline Med Surg. 2017 Feb;19(2):224-230. doi: 10.1177/1098612X15623319. Epub 2016 Jul 10.
Objectives A xenogeneic human tyrosinase DNA vaccine was developed for treatment of dogs with oral malignant melanoma (Oncept; Merial). No studies have evaluated the safety or efficacy of this vaccine in cats. The purpose of this study was to evaluate the safety of the canine melanoma vaccine in cats diagnosed with melanoma. Methods Medical records were reviewed from cats diagnosed with malignant melanoma and treated with the canine melanoma DNA vaccine (Oncept). Data regarding signalment, melanoma location, treatments received, vaccine adverse effects and cause of death were collected. Results A total of 114 melanoma vaccines were administered to 24 cats. Seven cats (11.4%) had clinical adverse effects from a total of 13 vaccines classified as grade 1 or 2 based on the Veterinary Cooperative Oncology Group's common terminology criteria for adverse events v1.1. These included pain on vaccine administration, brief muscle fasciculation, transient inappetence, depression, nausea and mild increase in pigmentation at the injection site. Nineteen cats were deceased at study close. The most common cause of death was melanoma (14 cats). Hematological and biochemical changes were observed in six cats, five of which had concurrent disease or treatments that likely caused or greatly contributed to the laboratory abnormalities found. Therefore, these adverse events were considered unlikely to be caused by the melanoma vaccine. One cat had transient grade 1 hypoalbuminemia, which was possibly caused by the vaccination but not thoroughly evaluated. Conclusions and relevance The canine melanoma DNA vaccine can be safely administered to cats, with minimal risk of adverse effects.
目的 开发一种用于治疗犬口腔恶性黑色素瘤的异种人酪氨酸酶DNA疫苗（Oncept；梅里亚公司）。尚无研究评估该疫苗在猫身上的安全性或有效性。本研究的目的是评估犬黑色素瘤疫苗在诊断为黑色素瘤的猫中的安全性。方法 回顾了诊断为恶性黑色素瘤并接受犬黑色素瘤DNA疫苗（Oncept）治疗的猫的病历。收集了有关动物特征、黑色素瘤位置、接受的治疗、疫苗不良反应和死亡原因的数据。结果 共向24只猫接种了114剂黑色素瘤疫苗。根据兽医肿瘤协作组不良事件通用术语标准v1.1，7只猫（11.4%）在总共13剂疫苗后出现了临床不良反应，分类为1级或2级。这些不良反应包括疫苗接种时的疼痛、短暂的肌肉抽搐、短暂的食欲不振、抑郁、恶心以及注射部位色素沉着轻度增加。在研究结束时，19只猫死亡。最常见的死亡原因是黑色素瘤（14只猫）。在6只猫中观察到血液学和生化变化，其中5只猫同时患有疾病或接受了可能导致或极大促成所发现的实验室异常的治疗。因此，这些不良事件被认为不太可能由黑色素瘤疫苗引起。1只猫出现短暂的1级低白蛋白血症，可能由疫苗接种引起，但未进行全面评估。结论及相关性 犬黑色素瘤DNA疫苗可以安全地接种给猫，不良反应风险极小。
